IT202100028388A1 - COSMETIC COMPOSITION - Google Patents
COSMETIC COMPOSITION Download PDFInfo
- Publication number
- IT202100028388A1 IT202100028388A1 IT102021000028388A IT202100028388A IT202100028388A1 IT 202100028388 A1 IT202100028388 A1 IT 202100028388A1 IT 102021000028388 A IT102021000028388 A IT 102021000028388A IT 202100028388 A IT202100028388 A IT 202100028388A IT 202100028388 A1 IT202100028388 A1 IT 202100028388A1
- Authority
- IT
- Italy
- Prior art keywords
- weight
- composition
- total weight
- total
- vitamin
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims description 78
- 239000002537 cosmetic Substances 0.000 title claims description 5
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 18
- 102000008186 Collagen Human genes 0.000 claims description 16
- 108010035532 Collagen Proteins 0.000 claims description 16
- 229920001436 collagen Polymers 0.000 claims description 16
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 claims description 13
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims description 12
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 12
- 102000016942 Elastin Human genes 0.000 claims description 11
- 108010014258 Elastin Proteins 0.000 claims description 11
- 229920002549 elastin Polymers 0.000 claims description 11
- 239000004475 Arginine Substances 0.000 claims description 10
- PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 claims description 10
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 claims description 10
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims description 10
- PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 claims description 10
- 229960002591 hydroxyproline Drugs 0.000 claims description 10
- FGMPLJWBKKVCDB-UHFFFAOYSA-N trans-L-hydroxy-proline Natural products ON1CCCC1C(O)=O FGMPLJWBKKVCDB-UHFFFAOYSA-N 0.000 claims description 10
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 claims description 9
- SNPLKNRPJHDVJA-ZETCQYMHSA-N D-panthenol Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCCO SNPLKNRPJHDVJA-ZETCQYMHSA-N 0.000 claims description 9
- 239000004471 Glycine Substances 0.000 claims description 9
- 229920002683 Glycosaminoglycan Polymers 0.000 claims description 9
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 claims description 9
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 claims description 9
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 claims description 9
- 229960003121 arginine Drugs 0.000 claims description 9
- 229960000310 isoleucine Drugs 0.000 claims description 9
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 claims description 9
- 229960002429 proline Drugs 0.000 claims description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 9
- 229920002385 Sodium hyaluronate Polymers 0.000 claims description 8
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 claims description 8
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 claims description 8
- 229960002449 glycine Drugs 0.000 claims description 8
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 claims description 8
- 229940101267 panthenol Drugs 0.000 claims description 8
- 235000020957 pantothenol Nutrition 0.000 claims description 8
- 239000011619 pantothenol Substances 0.000 claims description 8
- 229940010747 sodium hyaluronate Drugs 0.000 claims description 8
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 claims description 8
- MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 claims description 7
- RGZSQWQPBWRIAQ-LSDHHAIUSA-N alpha-Bisabolol Natural products CC(C)=CCC[C@@](C)(O)[C@@H]1CCC(C)=CC1 RGZSQWQPBWRIAQ-LSDHHAIUSA-N 0.000 claims description 7
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 claims description 7
- 229960002442 glucosamine Drugs 0.000 claims description 7
- 239000010460 hemp oil Substances 0.000 claims description 7
- 229930003427 Vitamin E Natural products 0.000 claims description 6
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims description 6
- 235000019165 vitamin E Nutrition 0.000 claims description 6
- 229940046009 vitamin E Drugs 0.000 claims description 6
- 239000011709 vitamin E Substances 0.000 claims description 6
- ZHUJMSMQIPIPTF-JMBSJVKXSA-N (2s)-2-[[(2s)-2-[[2-[[(2r)-2-[[(2s)-2-amino-3-(4-hydroxyphenyl)propanoyl]amino]propanoyl]amino]acetyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoic acid Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(O)=O)NC(=O)CNC(=O)[C@@H](C)NC(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=CC=C1 ZHUJMSMQIPIPTF-JMBSJVKXSA-N 0.000 claims description 5
- AJLNZWYOJAWBCR-OOPVGHQCSA-N (4s)-4-acetamido-5-[[(2s)-1-[[(2s)-1-[[(2s)-5-amino-1-[[(2s)-1-[[(2s)-1-amino-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-4-methylsulfanyl-1-oxobutan-2-yl]amino]-4-car Chemical compound OC(=O)CC[C@H](NC(C)=O)C(=C)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCN=C(N)N)C(N)=O AJLNZWYOJAWBCR-OOPVGHQCSA-N 0.000 claims description 5
- OPJWPPVYCOPDCM-UHFFFAOYSA-N 2-ethylhexyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(CC)CCCC OPJWPPVYCOPDCM-UHFFFAOYSA-N 0.000 claims description 5
- 241000283690 Bos taurus Species 0.000 claims description 5
- 229920000881 Modified starch Polymers 0.000 claims description 5
- 239000004368 Modified starch Substances 0.000 claims description 5
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 claims description 5
- 229940095094 acetyl hexapeptide-8 Drugs 0.000 claims description 5
- 108010006338 acetyl-glutamyl-glutamyl-methionyl-glutaminyl-arginyl-argininamide Proteins 0.000 claims description 5
- 239000003963 antioxidant agent Substances 0.000 claims description 5
- 230000003078 antioxidant effect Effects 0.000 claims description 5
- 235000006708 antioxidants Nutrition 0.000 claims description 5
- 239000003995 emulsifying agent Substances 0.000 claims description 5
- 229960003720 enoxolone Drugs 0.000 claims description 5
- 239000003797 essential amino acid Substances 0.000 claims description 5
- 235000020776 essential amino acid Nutrition 0.000 claims description 5
- 235000019426 modified starch Nutrition 0.000 claims description 5
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 claims description 5
- RMGVATURDVPNOZ-UHFFFAOYSA-M potassium;hexadecyl hydrogen phosphate Chemical compound [K+].CCCCCCCCCCCCCCCCOP(O)([O-])=O RMGVATURDVPNOZ-UHFFFAOYSA-M 0.000 claims description 5
- LADGBHLMCUINGV-UHFFFAOYSA-N tricaprin Chemical compound CCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCC)COC(=O)CCCCCCCCC LADGBHLMCUINGV-UHFFFAOYSA-N 0.000 claims description 5
- 235000019155 vitamin A Nutrition 0.000 claims description 5
- 239000011719 vitamin A Substances 0.000 claims description 5
- 229940045997 vitamin a Drugs 0.000 claims description 5
- CHHHXKFHOYLYRE-UHFFFAOYSA-M 2,4-Hexadienoic acid, potassium salt (1:1), (2E,4E)- Chemical compound [K+].CC=CC=CC([O-])=O CHHHXKFHOYLYRE-UHFFFAOYSA-M 0.000 claims description 4
- 235000020759 St. John’s wort extract Nutrition 0.000 claims description 4
- 229960000541 cetyl alcohol Drugs 0.000 claims description 4
- 239000002304 perfume Substances 0.000 claims description 4
- 239000004302 potassium sorbate Substances 0.000 claims description 4
- 235000010241 potassium sorbate Nutrition 0.000 claims description 4
- 229940069338 potassium sorbate Drugs 0.000 claims description 4
- 229960003471 retinol Drugs 0.000 claims description 4
- 235000020944 retinol Nutrition 0.000 claims description 4
- 239000011607 retinol Substances 0.000 claims description 4
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 claims description 4
- 235000010234 sodium benzoate Nutrition 0.000 claims description 4
- 239000004299 sodium benzoate Substances 0.000 claims description 4
- 229940099416 st. john's wort extract Drugs 0.000 claims description 4
- 239000004408 titanium dioxide Substances 0.000 claims description 4
- 235000013311 vegetables Nutrition 0.000 claims description 4
- 239000011787 zinc oxide Substances 0.000 claims description 4
- 210000003491 skin Anatomy 0.000 description 28
- 230000015572 biosynthetic process Effects 0.000 description 11
- 239000006071 cream Substances 0.000 description 8
- 238000003786 synthesis reaction Methods 0.000 description 8
- 230000037303 wrinkles Effects 0.000 description 8
- 229940024606 amino acid Drugs 0.000 description 7
- 150000001413 amino acids Chemical class 0.000 description 7
- 239000013065 commercial product Substances 0.000 description 7
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 6
- 230000032683 aging Effects 0.000 description 5
- 230000036571 hydration Effects 0.000 description 5
- 238000006703 hydration reaction Methods 0.000 description 5
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 4
- 230000003110 anti-inflammatory effect Effects 0.000 description 4
- 230000001153 anti-wrinkle effect Effects 0.000 description 4
- FLKYBGKDCCEQQM-WYUVZMMLSA-M cefazolin sodium Chemical compound [Na+].S1C(C)=NN=C1SCC1=C(C([O-])=O)N2C(=O)[C@@H](NC(=O)CN3N=NN=C3)[C@H]2SC1 FLKYBGKDCCEQQM-WYUVZMMLSA-M 0.000 description 4
- 210000002808 connective tissue Anatomy 0.000 description 4
- 230000001737 promoting effect Effects 0.000 description 4
- WTVHAMTYZJGJLJ-UHFFFAOYSA-N (+)-(4S,8R)-8-epi-beta-bisabolol Natural products CC(C)=CCCC(C)C1(O)CCC(C)=CC1 WTVHAMTYZJGJLJ-UHFFFAOYSA-N 0.000 description 3
- RGZSQWQPBWRIAQ-CABCVRRESA-N (-)-alpha-Bisabolol Chemical compound CC(C)=CCC[C@](C)(O)[C@H]1CCC(C)=CC1 RGZSQWQPBWRIAQ-CABCVRRESA-N 0.000 description 3
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 3
- MPDGHEJMBKOTSU-YKLVYJNSSA-N 18beta-glycyrrhetic acid Chemical compound C([C@H]1C2=CC(=O)[C@H]34)[C@@](C)(C(O)=O)CC[C@]1(C)CC[C@@]2(C)[C@]4(C)CC[C@@H]1[C@]3(C)CC[C@H](O)C1(C)C MPDGHEJMBKOTSU-YKLVYJNSSA-N 0.000 description 3
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 description 3
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 3
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 3
- 229940036350 bisabolol Drugs 0.000 description 3
- HHGZABIIYIWLGA-UHFFFAOYSA-N bisabolol Natural products CC1CCC(C(C)(O)CCC=C(C)C)CC1 HHGZABIIYIWLGA-UHFFFAOYSA-N 0.000 description 3
- 210000004207 dermis Anatomy 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 210000002744 extracellular matrix Anatomy 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 229920002674 hyaluronan Polymers 0.000 description 3
- 229960003160 hyaluronic acid Drugs 0.000 description 3
- 229960000890 hydrocortisone Drugs 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 206010001488 Aggression Diseases 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- 102000012422 Collagen Type I Human genes 0.000 description 2
- 108010022452 Collagen Type I Proteins 0.000 description 2
- MPDGHEJMBKOTSU-UHFFFAOYSA-N Glycyrrhetinsaeure Natural products C12C(=O)C=C3C4CC(C)(C(O)=O)CCC4(C)CCC3(C)C1(C)CCC1C2(C)CCC(O)C1(C)C MPDGHEJMBKOTSU-UHFFFAOYSA-N 0.000 description 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 102000016611 Proteoglycans Human genes 0.000 description 2
- 108010067787 Proteoglycans Proteins 0.000 description 2
- VYGQUTWHTHXGQB-FFHKNEKCSA-N Retinol Palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C VYGQUTWHTHXGQB-FFHKNEKCSA-N 0.000 description 2
- 230000016571 aggressive behavior Effects 0.000 description 2
- DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 description 2
- 150000004263 amino monosaccharides Chemical class 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 210000001612 chondrocyte Anatomy 0.000 description 2
- 230000035876 healing Effects 0.000 description 2
- 230000000887 hydrating effect Effects 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 229940055726 pantothenic acid Drugs 0.000 description 2
- 235000019161 pantothenic acid Nutrition 0.000 description 2
- 239000011713 pantothenic acid Substances 0.000 description 2
- 230000008447 perception Effects 0.000 description 2
- 230000001172 regenerating effect Effects 0.000 description 2
- 230000008439 repair process Effects 0.000 description 2
- 230000008591 skin barrier function Effects 0.000 description 2
- 230000037067 skin hydration Effects 0.000 description 2
- 230000004936 stimulating effect Effects 0.000 description 2
- 210000000434 stratum corneum Anatomy 0.000 description 2
- VEVRNHHLCPGNDU-MUGJNUQGSA-N (2s)-2-amino-5-[1-[(5s)-5-amino-5-carboxypentyl]-3,5-bis[(3s)-3-amino-3-carboxypropyl]pyridin-1-ium-4-yl]pentanoate Chemical compound OC(=O)[C@@H](N)CCCC[N+]1=CC(CC[C@H](N)C(O)=O)=C(CCC[C@H](N)C([O-])=O)C(CC[C@H](N)C(O)=O)=C1 VEVRNHHLCPGNDU-MUGJNUQGSA-N 0.000 description 1
- FUFLCEKSBBHCMO-UHFFFAOYSA-N 11-dehydrocorticosterone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 FUFLCEKSBBHCMO-UHFFFAOYSA-N 0.000 description 1
- 235000007866 Chamaemelum nobile Nutrition 0.000 description 1
- MFYSYFVPBJMHGN-ZPOLXVRWSA-N Cortisone Chemical compound O=C1CC[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 MFYSYFVPBJMHGN-ZPOLXVRWSA-N 0.000 description 1
- MFYSYFVPBJMHGN-UHFFFAOYSA-N Cortisone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)(O)C(=O)CO)C4C3CCC2=C1 MFYSYFVPBJMHGN-UHFFFAOYSA-N 0.000 description 1
- 235000004866 D-panthenol Nutrition 0.000 description 1
- 239000011703 D-panthenol Substances 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 208000010201 Exanthema Diseases 0.000 description 1
- 244000303040 Glycyrrhiza glabra Species 0.000 description 1
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 description 1
- 206010019345 Heat stroke Diseases 0.000 description 1
- 235000017443 Hedysarum boreale Nutrition 0.000 description 1
- 235000007858 Hedysarum occidentale Nutrition 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 239000000232 Lipid Bilayer Substances 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 244000042664 Matricaria chamomilla Species 0.000 description 1
- 235000007232 Matricaria chamomilla Nutrition 0.000 description 1
- 239000004909 Moisturizer Substances 0.000 description 1
- 235000011925 Passiflora alata Nutrition 0.000 description 1
- 235000000370 Passiflora edulis Nutrition 0.000 description 1
- 235000011922 Passiflora incarnata Nutrition 0.000 description 1
- 240000002690 Passiflora mixta Species 0.000 description 1
- 235000013750 Passiflora mixta Nutrition 0.000 description 1
- 235000013731 Passiflora van volxemii Nutrition 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical group C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 1
- VYGQUTWHTHXGQB-UHFFFAOYSA-N Retinol hexadecanoate Natural products CCCCCCCCCCCCCCCC(=O)OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C VYGQUTWHTHXGQB-UHFFFAOYSA-N 0.000 description 1
- 208000007180 Sunstroke Diseases 0.000 description 1
- 229930003571 Vitamin B5 Natural products 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 235000020661 alpha-linolenic acid Nutrition 0.000 description 1
- UPOYFZYFGWBUKL-UHFFFAOYSA-N amiphenazole Chemical compound S1C(N)=NC(N)=C1C1=CC=CC=C1 UPOYFZYFGWBUKL-UHFFFAOYSA-N 0.000 description 1
- 229950001798 amiphenazole Drugs 0.000 description 1
- 230000003712 anti-aging effect Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- FAPWYRCQGJNNSJ-UBKPKTQASA-L calcium D-pantothenic acid Chemical compound [Ca+2].OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O.OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O FAPWYRCQGJNNSJ-UBKPKTQASA-L 0.000 description 1
- 229960002079 calcium pantothenate Drugs 0.000 description 1
- 230000001914 calming effect Effects 0.000 description 1
- 229930003827 cannabinoid Natural products 0.000 description 1
- 239000003557 cannabinoid Substances 0.000 description 1
- 229940065144 cannabinoids Drugs 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 210000000736 corneocyte Anatomy 0.000 description 1
- 229960004544 cortisone Drugs 0.000 description 1
- 239000008278 cosmetic cream Substances 0.000 description 1
- STORWMDPIHOSMF-UHFFFAOYSA-N decanoic acid;octanoic acid;propane-1,2,3-triol Chemical compound OCC(O)CO.CCCCCCCC(O)=O.CCCCCCCCCC(O)=O STORWMDPIHOSMF-UHFFFAOYSA-N 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 210000004177 elastic tissue Anatomy 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 201000005884 exanthem Diseases 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 102000034240 fibrous proteins Human genes 0.000 description 1
- 108091005899 fibrous proteins Proteins 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 239000003349 gelling agent Substances 0.000 description 1
- 150000004676 glycans Polymers 0.000 description 1
- 239000001947 glycyrrhiza glabra rhizome/root Substances 0.000 description 1
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical class O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 239000002085 irritant Substances 0.000 description 1
- 239000002973 irritant agent Substances 0.000 description 1
- RGXCTRIQQODGIZ-UHFFFAOYSA-O isodesmosine Chemical compound OC(=O)C(N)CCCC[N+]1=CC(CCC(N)C(O)=O)=CC(CCC(N)C(O)=O)=C1CCCC(N)C(O)=O RGXCTRIQQODGIZ-UHFFFAOYSA-O 0.000 description 1
- 229960004488 linolenic acid Drugs 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 230000001333 moisturizer Effects 0.000 description 1
- 230000003020 moisturizing effect Effects 0.000 description 1
- 230000003387 muscular Effects 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 235000020660 omega-3 fatty acid Nutrition 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 229940068065 phytosterols Drugs 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 150000004804 polysaccharides Polymers 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
- 206010037844 rash Diseases 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 229940108325 retinyl palmitate Drugs 0.000 description 1
- 235000019172 retinyl palmitate Nutrition 0.000 description 1
- 239000011769 retinyl palmitate Substances 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 230000037384 skin absorption Effects 0.000 description 1
- 231100000274 skin absorption Toxicity 0.000 description 1
- 231100000046 skin rash Toxicity 0.000 description 1
- 239000000779 smoke Substances 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 150000003408 sphingolipids Chemical class 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- 210000002437 synoviocyte Anatomy 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000009492 vitamin B5 Nutrition 0.000 description 1
- 239000011675 vitamin B5 Substances 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/34—Alcohols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
- A61K8/42—Amides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
- A61K8/44—Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/60—Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/60—Sugars; Derivatives thereof
- A61K8/602—Glycosides, e.g. rutin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
- A61K8/65—Collagen; Gelatin; Keratin; Derivatives or degradation products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/67—Vitamins
- A61K8/671—Vitamin A; Derivatives thereof, e.g. ester of vitamin A acid, ester of retinol, retinol, retinal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/67—Vitamins
- A61K8/678—Tocopherol, i.e. vitamin E
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/73—Polysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/73—Polysaccharides
- A61K8/735—Mucopolysaccharides, e.g. hyaluronic acid; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/92—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof
- A61K8/922—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof of vegetable origin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Birds (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Emergency Medicine (AREA)
- Cosmetics (AREA)
Description
DESCRIZIONE DESCRIPTION
del brevetto per invenzione industriale dal titolo: of the patent for industrial invention entitled:
?COMPOSIZIONE COSMETICA? ?COSMETIC COMPOSITION?
La presente invenzione ? relativa a una composizione e al suo utilizzo come cosmetico. This invention? relating to a composition and its use as a cosmetic.
Stato dell?Arte State of art
Man mano che la pelle invecchia, diventa sempre pi? sottile e fragile, la rigenerazione cellulare diventa pi? lenta e passa dalle normali 3-4 settimane a 5-6 settimane. Le rughe sono una conseguenza della diminuzione dell?elasticit? della pelle, e non solo dell?invecchiamento. E? possibile riscontrare rughe anche in soggetti molto giovani. Questo ? dovuto al fatto che le rughe si formano dove avvengono i movimenti muscolari pi? importanti, che richiedono alla pelle un?elasticit? particolare. As the skin ages, it becomes more and more thin and fragile, cell regeneration becomes more slow and goes from the normal 3-4 weeks to 5-6 weeks. Wrinkles are a consequence of decreased elasticity? of the skin, and not just of aging. AND? It is possible to find wrinkles even in very young subjects. This ? due to the fact that wrinkles form where the most muscular movements occur? important, which require the skin to have elasticity? particular.
Al giorno d?oggi l?immagine ? molto importante e tanto le donne quanto gli uomini desiderano minimizzare le rughe che si formano in particolare sul viso. Vi sono in commercio numerose creme cosmetiche per combattere i segni del tempo. Nowadays the image is very important and both women and men want to minimize the wrinkles that form in particular on the face. There are numerous cosmetic creams on the market to combat the signs of aging.
Tuttavia, vi ? la continua richiesta e necessit? di migliorare la composizione di tali creme, utilizzando prodotti pi? eficaci e componenti non aggressive per la pelle. However, there ? the continuous request and necessity? to improve the composition of these creams, using more products? effective and non-aggressive components for the skin.
? pertanto scopo della presente invenzione fornire una nuova composizione che migliori l?aspetto della pelle, rigenerandola e proteggendola dalle aggressioni dell?ambiente esterno. ? therefore the aim of the present invention is to provide a new composition that improves the appearance of the skin, regenerating it and protecting it from the aggressions of the external environment.
Secondo la presente invenzione, tale scopo viene raggiunto mediante la composizione secondo la rivendicazione 1. According to the present invention, this purpose is achieved by the composition according to claim 1.
Un altro scopo della presente invenzione ? di fornire usi della suddetta composizione come definiti nelle rivendicazioni 7 a 9. Another purpose of the present invention? to provide uses of the aforementioned composition as defined in claims 7 to 9.
Descrizione dettagliata dell?invenzione Detailed description of the invention
La composizione secondo la presente invenzione comprende: da 2 a 4 % in peso di collagene idrolizzato bovino; da 0,5 a 7 % in peso di almeno un aminoacido essenziale selezionato dal gruppo costituito da arginina, idrossiprolina, glicina, prolina, isoleucina, e combinazioni di essi; da 0,25 a 1 % in peso di elastina idrolizzata 20%; da 0,4 a 1,2 % in peso di sodio ialuronato con peso molecolare da 100 a 400 kDa; da 0,25 a 1 % in peso di glicosaminoglicani; da 0,4 a 1 % in peso di glucosamina; da 0,5 a 2 % in peso di acido 18 ?-glicirretico; da 0,5 a 2 % in peso di alfabisabolo, da 2 a 4 % in peso di estratto liposolubile di iperico, da 3 a 7 % in peso di olio di canapa, da 0,5 a 2 % in peso di vitamina E; da 0,5 a 2 % in peso sul peso totale della composizione di pantenolo; da 0,1 a 0,5 % in peso sul peso totale della composizione di vitamina A (retinolo); e acqua. The composition according to the present invention includes: from 2 to 4% by weight of hydrolyzed bovine collagen; from 0.5 to 7% by weight of at least one essential amino acid selected from the group consisting of arginine, hydroxyproline, glycine, proline, isoleucine, and combinations thereof; from 0.25 to 1% by weight of hydrolyzed elastin 20%; from 0.4 to 1.2% by weight of sodium hyaluronate with a molecular weight of from 100 to 400 kDa; from 0.25 to 1% by weight of glycosaminoglycans; from 0.4 to 1% by weight of glucosamine; from 0.5 to 2% by weight of 18?-glycyrrhetinic acid; from 0.5 to 2% by weight of alfabisabol, from 2 to 4% by weight of fat-soluble St. John's wort extract, from 3 to 7% by weight of hemp oil, from 0.5 to 2% by weight of vitamin E; from 0.5 to 2% by weight on the total weight of the panthenol composition; from 0.1 to 0.5% by weight on the total weight of the vitamin A (retinol) composition; and water.
Nella presente descrizione, le percentuali in peso sono espresse rispetto al peso totale della composizione a meno che diversamente indicato. In this description, weight percentages are expressed relative to the total weight of the composition unless otherwise indicated.
Il collagene di tipo I costituisce la maggior parte del collagene presente nel nostro organismo e si trova soprattutto nella pelle, dove rappresenta il principale componente strutturale della matrice extracellulare del derma. Il collagene idrolizzato si ottiene sottoponendo il collagene nativo di tipo I a processi di idrolisi con lo scopo di ridurlo in frammenti proteici di minore peso molecolare. Scomporre il collagene nativo in un certo numero di catene peptidiche, pi? o meno lunghe, ha lo scopo di abbatterne il potere gelificante e favorirne l'assorbimento cutaneo. Le concentrazioni di collagene nella pelle tendono a ridursi con l'invecchiamento, sottraendo alla cute turgore e compattezza; il collagene idrolizzato viene quindi utilizzato anche come trattamento anti-aging a livello cutaneo. Il collagene presenta un profilo aminoacidico molto ampio, inoltre ? particolarmente ricco degli amminoacidi necessari alla sintesi del collagene stesso, come prolina ed idrossiprolina, spesso carenti nella dieta. Scopo primario dell'integrazione di collagene ? dunque quello di promuovere e stimolare la sintesi dello stesso all'interno dell'organismo, fornendo alle cellule il pool di amminoacidi necessario. La sintesi di collagene pu? essere potenziata anche dall'integrazione di singoli amminoacidi essenziali, come arginina, idrossiprolina, glicina, prolina ed isoleucina. Il collagene bovino utilizzato nella composizione secondo la presente invenzione ? particolarmente efficace anche sulla cute umana. Type I collagen constitutes the majority of collagen present in our body and is found mainly in the skin, where it represents the main structural component of the extracellular matrix of the dermis. Hydrolyzed collagen is obtained by subjecting native type I collagen to hydrolysis processes with the aim of reducing it into protein fragments of lower molecular weight. Breaking down native collagen into a certain number of peptide chains, more? or less long, has the aim of reducing its gelling power and promoting its skin absorption. Collagen concentrations in the skin tend to reduce with aging, depriving the skin of firmness and firmness; hydrolyzed collagen is therefore also used as an anti-aging treatment on the skin. Collagen has a very broad amino acid profile, moreover? particularly rich in the amino acids necessary for the synthesis of collagen itself, such as proline and hydroxyproline, often lacking in the diet. Primary purpose of collagen supplementation? therefore that of promoting and stimulating its synthesis within the organism, providing the cells with the necessary pool of amino acids. Collagen synthesis can also be enhanced by the integration of individual essential amino acids, such as arginine, hydroxyproline, glycine, proline and isoleucine. The bovine collagen used in the composition according to the present invention? particularly effective also on human skin.
Preferibilmente, la composizione comprende arginina, idrossiprolina, glicina, prolina e isoleucina. Preferably, the composition includes arginine, hydroxyproline, glycine, proline and isoleucine.
Il sodio ialuronato extra LW (peso molecolare da 100 a 400 kDa) ? di origine biotecnologica e presenta un livello di impurit? molto bassa; ? anche da sottolineare l?altissima biocompatibilit? e degradabilit?. Questo ? un particolare peso molto utile in dermocosmesi per la sua profonda idratazione. Il sodio ialuronato ? il sale sodico dell'acido ialuronico, uno dei principali componenti dei tessuti connettivi. Svolge la funzione di mantenere il corretto grado di idratazione, turgidit?, plasticit? e viscosit?. Questa molecola penetra facilmente nella pelle e ha la capacit? di trattenere acqua (fino a 1.000 volte il suo peso) e di riempire gli spazi tra collagene ed elastina: idrata la pelle, permettendole di trattenere l'acqua e di creare un effetto volumizzante. Poich? la pelle perde naturalmente la sua composizione acquosa durante il naturale processo di invecchiamento, il sodio ialuronato pu? sostituire parte dell'acqua persa nel derma, contribuendo a combattere le rughe e altri segni dell'invecchiamento. A seconda del suo peso molecolare, il sodio ialuronato riesce a penetrare in maniera pi? o meno profonda nei vari strati del derma: pi? ? basso il suo peso molecolare, pi? in profondit? arriva la molecola, riuscendo a svolgere un'azione antirughe pi? mirata. Extra LW sodium hyaluronate (molecular weight from 100 to 400 kDa) is of biotechnological origin and has a level of impurity? very low; ? Also to underline the very high biocompatibility? and degradability. This ? a particular weight that is very useful in dermocosmetics for its deep hydration. Sodium hyaluronate? the sodium salt of hyaluronic acid, one of the main components of connective tissues. It carries out the function of maintaining the correct level of hydration, turgidity, plasticity. and viscosity?. This molecule easily penetrates the skin and has the ability to retain water (up to 1,000 times its weight) and to fill the spaces between collagen and elastin: hydrates the skin, allowing it to retain water and create a volumizing effect. Since? skin naturally loses its aqueous composition during the natural aging process, sodium hyaluronate can replace some of the water lost in the dermis, helping to fight wrinkles and other signs of aging. Depending on its molecular weight, sodium hyaluronate is able to penetrate more effectively. or less deep in the various layers of the dermis: more? ? its molecular weight is low, the more in depth? the molecule arrives, managing to carry out a more anti-wrinkle action? targeted.
L?elastina idrolizzata ? un agente filmogeno ed idratante, grazie al suo elevato contenuto in aminoacidi ? in grado di assicurare un significativo aumento dell?idratazione cutanea e del grado di elasticit? e turgore della cute. Infatti l?elastina, assieme alle fibre collagene e ai mucopolisaccaridi, costituisce in forma di fibre elastiche una delle strutture portanti del connettivo dermico. In virt? delle caratteristiche intrinseche proprie delle catene molecolari che si distribuiscono uniformemente sullo strato corneo formando un film macromolecolare, ? in grado di fare diminuire sensibilmente le inevitabili perdite idriche, contribuendo in maniera indiretta alla umettazione dei corneociti, mantenendo la pelle sana e di gradevole aspetto. L?elastina possiede anche due aminoacidi particolari, desmosina e isodesmosina; le loro strutture possono essere considerate come il risultato dell?unione di quattro molecole di lisina, con formazione di un anello piridinico sostituito che permette ai due aminoacidi di unire in posizione radiale quattro catene polipeptidiche. Grazie a ci? l?elastina, a differenza delle altre proteine fibrose pu? allungarsi nelle due direzioni, potenziando la funzione di sostantivit? propria di tali proteine. Hydrolyzed elastin? a film-forming and hydrating agent, thanks to its high amino acid content? capable of ensuring a significant increase in skin hydration and the degree of elasticity? and firmness of the skin. In fact, elastin, together with collagen fibers and mucopolysaccharides, constitutes in the form of elastic fibers one of the load-bearing structures of the dermal connective tissue. By virtue? of the intrinsic characteristics of the molecular chains that are uniformly distributed on the stratum corneum forming a macromolecular film,? capable of significantly reducing the inevitable water losses, contributing indirectly to the humectation of the corneocytes, keeping the skin healthy and pleasant in appearance. Elastin also has two particular amino acids, desmosine and isodesmosine; their structures can be considered as the result of the union of four lysine molecules, with the formation of a substituted pyridine ring which allows the two amino acids to join four polypeptide chains in a radial position. Thanks to that? elastin, unlike other fibrous proteins, can stretch in both directions, enhancing the function of substantivity? specific to these proteins.
Glicosaminoglicani dei tessuti connettivi sono lunghe catene polimeriche formate da un concatenamento lineare di unit? disaccaridiche identiche unite linearmente tra loro. I glicosaminoglicani, legandosi a proteine per andare a formare i proteoglicani, sono molecole tipiche della sostanza fondamentale amorfa che compone la matrice extracellulare dei tessuti connettivi, conferendo alcune delle loro caratteristiche tipiche, come appunto la capacit? di idratarsi abbondantemente. Ottimo umettante, idratante e gelificante naturale. Composto da mucopolisaccaridi ad alto peso molecolare, svolge un?eccellente azione filmogena e idratante sulla cute e contribuisce in maniera decisa a riportare alla norma l?equilibrio idrolipidico cutaneo. Glycosaminoglycans of connective tissues are long polymeric chains formed by a linear chain of units identical disaccharides joined linearly to each other. Glycosaminoglycans, by binding to proteins to form proteoglycans, are typical molecules of the amorphous fundamental substance that makes up the extracellular matrix of connective tissues, giving some of their typical characteristics, such as the to hydrate abundantly. Excellent humectant, moisturizer and natural gelling agent. Composed of high molecular weight mucopolysaccharides, it has an excellent film-forming and hydrating action on the skin and contributes decisively to bringing the skin's hydrolipidic balance back to normal.
L'acido 18beta-glicirretico ? un metabolita della glicirrizina, una saponina contenuta nella radice di liquirizia; ? strutturalmente simile al cortisolo, del quale potenzia l'attivit? antiinfiammatoria inibendone l'inattivazione intracellulare. L?acido glicirretico possiede propriet? antinfiammatorie, lenitive e antiirritanti. Interviene nell?ossidazione del cortisolo (idrocortisone) in cortisone, nella sintesi e nella liberazione di istamina, nonch? nell?aumento della concentrazione calcica intracellulare indotta da un antigene. 18beta-glycyrrhetinic acid? a metabolite of glycyrrhizin, a saponin contained in licorice root; ? structurally similar to cortisol, whose activity it enhances? anti-inflammatory by inhibiting its intracellular inactivation. Glycyrrhetinic acid has properties anti-inflammatory, soothing and anti-irritant. It intervenes in the oxidation of cortisol (hydrocortisone) into cortisone, in the synthesis and release of histamine, as well as? in the increase in intracellular calcium concentration induced by an antigen.
Bisabololo ? l??-bisabololo comunemente ?bisabololo?, un alcol naturale che si ottiene per distillazione dell?olio essenziale di camomilla. Il bisabololo ? amico della pelle per le sue diverse propriet?: lenitivo, anti-infiammatorio ed addolcente, cicatrizzante e riparatore. Bisabolol? l??-bisabolol commonly "bisabolol", a natural alcohol obtained by distillation of chamomile essential oil. Bisabolol? friend of the skin for its various properties: soothing, anti-inflammatory and softening, healing and repairing.
La glucosammina (o glucosamina) ? un amminomonosaccaride naturalmente presente nell'organismo umano. Essa ? un elemento costituzionale di preziose molecole facenti parte della matrice extracellulare. Rientra nelle catene polisaccaridiche dei glicosaminoglicani della matrice cartilaginea (acido ialuronico incluso). Alcuni studi hanno mostrato che la glucosammina ? in grado di favorirne la sintesi da parte dei condrociti, cos? come ? in grado di stimolare la sintesi di proteoglicani, sempre da parte dei condrociti, e di favorire la sintesi di acido ialuronico da parte dei sinoviociti. Oltre a ci?, sembra che questo amminomonosaccaride sia in grado di esercitare anche una modesta attivit? antinfiammatoria. Glucosamine (or glucosamine)? an aminomonosaccharide naturally present in the human body. It? a constitutional element of precious molecules forming part of the extracellular matrix. It is part of the polysaccharide chains of glycosaminoglycans of the cartilaginous matrix (including hyaluronic acid). Some studies have shown that glucosamine is capable of promoting its synthesis by chondrocytes, so? as ? capable of stimulating the synthesis of proteoglycans, again by chondrocytes, and of promoting the synthesis of hyaluronic acid by synoviocytes. In addition to this, it seems that this aminomonosaccharide is capable of exercising even a modest activity. anti-inflammatory.
L'olio di canapa ? una delle poche fonti vegetali di acido alfa linolenico. In particolare, l'olio di semi di canapa ? noto per il suo ottimale equilibrio tra omega-3 e omega-6. Nell'olio di canapa sono presenti anche quantit? significative di amminoacidi, essenziali al corretto funzionamento dell'organismo; numerose vitamine, tra cui A, E, B1, B2, PP, C; sali minerali come ferro, calcio, magnesio, potassio, fosforo, fitosteroli e cannabinoidi. Hemp oil? one of the few plant sources of alpha linolenic acid. In particular, hemp seed oil is ? known for its optimal balance between omega-3 and omega-6. In hemp oil there are also quantities of significant amounts of amino acids, essential for the correct functioning of the body; numerous vitamins, including A, E, B1, B2, PP, C; mineral salts such as iron, calcium, magnesium, potassium, phosphorus, phytosterols and cannabinoids.
Il pantenolo o provitamina B5 ? la forma alcolica ridotta dell'acido pantotenico (vitamina B5). Il pantenolo agisce per via topica inducendo la sintesi di un precursore degli acidi grassi e degli sfingolipidi, essenziali ai fini della costituzione del doppio strato lipidico dello strato corneo; contribuisce a riparare la barriera cutanea, a migliorare l?idratazione, a diminuire la rugosit? e a ridurre indirettamente l?infiammazione e una volta ripristinata, la funzione barriera della pelle, limita la penetrazione di agenti potenzialmente irritanti. Il pantenolo inoltre stimolando la crescita cellulare, diminuisce i tempi di cicatrizzazione delle ferite. Esercita inoltre un?azione calmante e curativa, ed ? quindi un ausilio in caso di colpo di sole e di forti eritemi cutanei. Nella pelle il pantenolo viene trasformato in acido pantotenico ad opera di alcuni enzimi. Esso favorisce una migliore idratazione cutanea in quanto penetra negli strati pi? profondi della pelle e vi fissa l?acqua, mantenendo la pelle pi? elastica e soda. Panthenol or provitamin B5? the reduced alcoholic form of pantothenic acid (vitamin B5). Panthenol acts topically by inducing the synthesis of a precursor of fatty acids and sphingolipids, essential for the formation of the lipid bilayer of the stratum corneum; helps repair the skin barrier, improve hydration, reduce roughness and to indirectly reduce inflammation and once restored, the skin's barrier function limits the penetration of potentially irritating agents. Panthenol also stimulates cell growth and reduces wound healing times. It also has a calming and healing action, and is therefore an aid in case of sunstroke and severe skin rashes. In the skin, panthenol is transformed into pantothenic acid by some enzymes. It promotes better skin hydration as it penetrates the deepest layers. deep in the skin and fixes the water there, keeping the skin more elastic and firm.
? stato sorprendentemente scoperto che la specifica combinazione di queste componenti contrastano la formazione di rughe e favoriscono la riduzione di quelle gi? formate. ? It was surprisingly discovered that the specific combination of these components counteract the formation of wrinkles and promote the reduction of those already formed.
Preferibilmente, tale composizione comprende inoltre una o pi? delle componenti selezionate dal gruppo costituito da: da 0,2 a 0,8 % in peso di potassio cetilfosfato, da 2 a 8 % in peso di glicerolo vegetale, da 0,1 a 0,5 % in peso di sodio benzoato, da 0,1 a 0,5 % in peso di potassio sorbato, da 0,1 a 0,6 % in peso di titanio biossido, da 0,1 a 0,5 % in peso di zinco ossido, da 0,5 a 2 % in peso di amido modificato, da 5 a 9 % in peso di caprylic capric triglyceride, da 5 a 15 % in peso di ethylhexyl stearate, da 1 a 3 % in peso di alcol cetilico, da 5 a 15 % in peso di acetil esapeptide-8 e pentapeptide-18. Preferably, this composition further comprises one or more of the components selected from the group consisting of: from 0.2 to 0.8% by weight of potassium cetylphosphate, from 2 to 8% by weight of vegetable glycerol, from 0.1 to 0.5% by weight of sodium benzoate, from 0.1 to 0.5 weight % potassium sorbate, 0.1 to 0.6 weight % titanium dioxide, 0.1 to 0.5 weight % zinc oxide, 0.5 to 2 % by weight of modified starch, 5 to 9 % by weight of caprylic capric triglyceride, 5 to 15 % by weight of ethylhexyl stearate, 1 to 3 % by weight of cetyl alcohol, 5 to 15 % by weight of acetyl hexapeptide-8 and pentapeptide-18.
La presenza di una o pi? di queste componenti favorisce ulteriormente l?effetto benefico della composizione. La composizione pu? comprendere inoltre da 3 a 7 % in peso di emulsificatore, o da 0,05 a 0,2 % in peso di antiossidante, o da 0,5 a 1 % in peso di profumo. Ancor pi? preferibilmente, la composizione comprende tutte le suddette componenti. The presence of one or more? of these components further favors the beneficial effect of the composition. The composition can further include from 3 to 7% by weight of emulsifier, or from 0.05 to 0.2% by weight of antioxidant, or from 0.5 to 1% by weight of perfume. Even more? preferably, the composition includes all the aforementioned components.
Il potassio cetilfosfato ? preferibilmente il prodotto commerciale Amphisol K (RES-PHARMA). L?arginina ? preferibilmente arginina-L cloridrato. L?elastina ? preferibilmente elastina idrolizzata 20% PF. Potassium cetylphosphate? preferably the commercial product Amphisol K (RES-PHARMA). Arginine? preferably arginine-L hydrochloride. Elastin? preferably hydrolysed elastin 20% PF.
L?emulsificatore ? preferibilmente il prodotto commerciale Emulium kappa MB (Gattefoss?). L?amido modificato ? preferibilmente il prodotto commerciale Dry-flo PC (ACEF). Il caprylic capric triglyceride ? preferibilmente il prodotto commerciale Tegosoft CT (ACEF). L?ethylhexyl stearate ? preferibilmente il prodotto commerciale Tegosoft OS (ACEF). L?antiossidante ? preferibilmente il prodotto commerciale Aperoxid TLA (Farmalabor). Acetil esapeptide-8 e pentapeptide-18 sono preferibilmente parte del prodotto commerciale Argirelox peptide solution (Lipotech). La vitamina A ? preferibilmente vitamina A palmitato 1700000UI (ACEF). La vitamina E ? preferibilmente in forma di vitamina E aetato. Il profumo ? preferibilmente forfumo di passiflora 4674 IPA (Muller & Kostner). The emulsifier? preferably the commercial product Emulium kappa MB (Gattefoss?). The modified starch is preferably the commercial product Dry-flo PC (ACEF). Caprylic capric triglyceride? preferably the commercial product Tegosoft CT (ACEF). L?ethylhexyl stearate ? preferably the commercial product Tegosoft OS (ACEF). The antioxidant? preferably the commercial product Aperoxid TLA (Farmalabor). Acetyl hexapeptide-8 and pentapeptide-18 are preferably part of the commercial product Argirelox peptide solution (Lipotech). Vitamin A? preferably vitamin A palmitate 1700000UI (ACEF). Vitamin E? preferably in the form of vitamin E aetate. The scent ? preferably passionflower smoke 4674 IPA (Muller & Kostner).
In una forma di realizzazione preferita, la composizione ? costituita da: In a preferred embodiment, the composition is consisting of:
- 3 % in peso sul peso totale della composizione di collagene idrolizzato bovino; - 3% by weight of the total weight of the bovine hydrolyzed collagen composition;
- da 1 a 5,8 % in peso sul peso totale della composizione di almeno un aminoacido essenziale selezionato dal gruppo costituito da arginina, idrossiprolina, glicina, prolina, isoleucina, e combinazioni di essi; - from 1 to 5.8% by weight on the total weight of the composition of at least one essential amino acid selected from the group consisting of arginine, hydroxyproline, glycine, proline, isoleucine, and combinations thereof;
- 0,5 % in peso sul peso totale della composizione di elastina idrolizzata 20%; - 0.5% by weight on the total weight of the 20% hydrolysed elastin composition;
- 0,8 % in peso sul peso totale della composizione di sodio ialuronato con peso molecolare da 100 a 400 kDa; - 0.8% by weight on the total weight of the sodium hyaluronate composition with a molecular weight of 100 to 400 kDa;
- 0,5 % in peso sul peso totale della composizione di glicosaminoglicani; - 0.5% by weight of the total weight of the glycosaminoglycan composition;
- 0,7 % in peso sul peso totale della composizione di glucosamina; - 0.7% by weight of the total weight of the glucosamine composition;
- 1 % in peso sul peso totale della composizione di acido 18 ?-glicirretico; - 1% by weight of the total weight of the 18?-glycyrrhetinic acid composition;
- 1 % in peso sul peso totale della composizione di alfa-bisabolo, - 1% by weight of the total weight of the alpha-bisabol composition,
- 3 % in peso sul peso totale della composizione di estratto liposolubile di iperico, - 3% by weight of the total weight of the composition of fat-soluble St. John's wort extract,
- 5 % in peso sul peso totale della composizione di olio di canapa, - 5% by weight of the total weight of the hemp oil composition,
- 1 % in peso sul peso totale della composizione di vitamina E, - 1% by weight of the total weight of the vitamin E composition,
- 1 % in peso sul peso totale della composizione di pantenolo, - 1% by weight of the total weight of the panthenol composition,
- 0,3 % in peso sul peso totale della composizione di vitamina A (retinolo), - 0.3% by weight of the total weight of the composition of vitamin A (retinol),
- 0,5 % in peso di potassio cetilfosfato, - 0.5% by weight of potassium cetylphosphate,
- 5 % in peso di glicerolo vegetale, - 5% by weight of vegetable glycerol,
- 0,3 % in peso di sodio benzoato, - 0.3% by weight sodium benzoate,
- 0,3 % in peso di potassio sorbato, - 0.3% by weight potassium sorbate,
- 0,35 % in peso di titanio biossido, - 0.35% by weight of titanium dioxide,
- 0,25 % in peso di zinco ossido, - 0.25% by weight of zinc oxide,
- 1 % in peso di amido modificato, - 1% by weight of modified starch,
- 7 % in peso di caprylic capric triglyceride, e - 7% by weight of caprylic capric triglyceride, e
- 10 % in peso di ethylhexyl stearate, - 10% by weight of ethylhexyl stearate,
- 2 % in peso di alcol cetilico, - 2% by weight of cetyl alcohol,
- 10 % in peso di acetil esapeptide-8 e pentapeptide-18, - 10% by weight of acetyl hexapeptide-8 and pentapeptide-18,
- 5 % in peso di emulsificatore, - 5% by weight of emulsifier,
- 0,1 % in peso di antiossidante, - 0.1% by weight of antioxidant,
- 0,750 % in peso di profumo, - 0.750% by weight of perfume,
- 33,850 % in peso di acqua. - 33.850% by weight of water.
Ancor pi? preferibilmente la composizione comprende 1 % in peso di arginina, 1 % in peso di idrossiprolina, 1,8 % in peso di glicina, 1 % in peso di prolina e 1 % in peso di isoleucina. Even more? preferably the composition comprises 1% by weight of arginine, 1% by weight of hydroxyproline, 1.8% by weight of glycine, 1% by weight of proline and 1% by weight of isoleucine.
La suddetta composizione ? preferibilmente in forma di pomata o crema per l?applicazione topica. The aforementioned composition? preferably in the form of an ointment or cream for topical application.
La composizione secondo la presente invenzione ? vantaggiosamente usata come cosmetico, in particolare per riparare, levigare e idratare la cute del viso e del corpo. The composition according to the present invention? advantageously used as a cosmetic, in particular to repair, smooth and hydrate the skin of the face and body.
La composizione in forma di crema ? preferibilmente applicata una volta al giorno, massaggiando fino ad assorbimento. La quantit? per applicazione ? da 6 a 10 g. The composition in cream form? preferably applied once a day, massaging until absorbed. The quantity? by application? 6 to 10 g.
La composizione secondo la forma di realizzazione descritta sopra ? stata testata rispetto a una crema idratante antirughe disponibile in commercio e ha dimostrato una migliore efficacia nella rigenerazione della pelle e nella protezione dalle aggressioni dell?ambiente esterno. La composizione secondo l'invenzione ha permesso di raffinare l'incarnato, ridurre le rughe e le linee di espressione, di restituire luminosit?, di migliorare l?elasticit? della pelle offrendo una sensazione di idratazione e morbidezza molto pi? accentuate rispetto alla composizione disponibile in commercio. The composition according to the embodiment described above is was tested compared to a commercially available anti-wrinkle moisturizing cream and demonstrated better effectiveness in regenerating the skin and protecting it from external environmental aggressions. The composition according to the invention made it possible to refine the complexion, reduce wrinkles and expression lines, restore luminosity, improve elasticity. of the skin offering a sensation of much more hydration and softness. accentuated compared to the composition available on the market.
Esempio Example
Sono stati reclutati 30 volontari di et? tra i 50 e 60 anni. I volontari sono stati divisi in due gruppi da 15. Ai volontari di un gruppo ? stata fornita la crema secondo l'invenzione (forma di realizzazione preferita) mentre ai volontari dell'altro gruppo ? stata fornita una crema antirughe commercializzata. I volontari non erano al corrente dell'appartenenza a un gruppo o l'altro. I volontari sono stati istruiti di applicare la crema una volta al giorno, preferibilmente di sera, per un mese di seguito. Sono state scattate foto prima del trattamento e dopo. 5 valutatori indipendenti hanno fornito un giudizio sul miglioramento dell'aspetto della pelle del viso dei volontari. Inoltre ai volontari ? stato somministrato un questionario sulla loro percezione della pelle dopo un mese di trattamento. Sia dalla valutazione dei 5 valutatori che dalla percezione dei volontari stessi ? risultato che la composizione secondo l'invenzione ? pi? efficace nel ridurre le rughe, migliorare l'aspetto della pelle, fornire una sensazione di idratazione ed elasticit? alla pelle, rispetto alla crema antirughe commerciale. 30 aged volunteers were recruited. between 50 and 60 years old. The volunteers were divided into two groups of 15. Volunteers in one group? the cream according to the invention was provided (preferred embodiment) while the volunteers of the other group were provided? A commercialized anti-wrinkle cream was provided. The volunteers were not aware of their membership in one group or the other. The volunteers were instructed to apply the cream once a day, preferably in the evening, for a month at a time. Photos were taken before the treatment and after. 5 independent evaluators provided a judgment on the improvement in the appearance of the volunteers' facial skin. Also to the volunteers? A questionnaire was administered on their perception of the skin after one month of treatment. Both from the evaluation of the 5 evaluators and from the perception of the volunteers themselves? result that the composition according to the invention is more? effective in reducing wrinkles, improving the appearance of the skin, providing a feeling of hydration and elasticity? to the skin, compared to commercial anti-wrinkle cream.
Claims (9)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IT102021000028388A IT202100028388A1 (en) | 2021-11-08 | 2021-11-08 | COSMETIC COMPOSITION |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IT102021000028388A IT202100028388A1 (en) | 2021-11-08 | 2021-11-08 | COSMETIC COMPOSITION |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IT202100028388A1 true IT202100028388A1 (en) | 2023-05-08 |
Family
ID=79602326
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IT102021000028388A IT202100028388A1 (en) | 2021-11-08 | 2021-11-08 | COSMETIC COMPOSITION |
Country Status (1)
| Country | Link |
|---|---|
| IT (1) | IT202100028388A1 (en) |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ITMI991772A1 (en) * | 1999-08-05 | 2001-02-05 | Maurizio Sirchi | COSMETIC COMPOSITION WITH ANTI-WRINKLE EFFECT |
| US20100055138A1 (en) * | 2006-12-20 | 2010-03-04 | Joel Margulies | Methods and topical formulations comprising colloidal metal for treating or preventing skin conditions |
| EP2253304B1 (en) * | 2009-02-23 | 2015-11-11 | Carmine Antropoli | Nifedipine-based compositions for anti-wrinkle treatments |
| US20210093539A1 (en) * | 2019-09-30 | 2021-04-01 | Concept Matrix Solutions | Topical cosmetic |
-
2021
- 2021-11-08 IT IT102021000028388A patent/IT202100028388A1/en unknown
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ITMI991772A1 (en) * | 1999-08-05 | 2001-02-05 | Maurizio Sirchi | COSMETIC COMPOSITION WITH ANTI-WRINKLE EFFECT |
| US20100055138A1 (en) * | 2006-12-20 | 2010-03-04 | Joel Margulies | Methods and topical formulations comprising colloidal metal for treating or preventing skin conditions |
| EP2253304B1 (en) * | 2009-02-23 | 2015-11-11 | Carmine Antropoli | Nifedipine-based compositions for anti-wrinkle treatments |
| US20210093539A1 (en) * | 2019-09-30 | 2021-04-01 | Concept Matrix Solutions | Topical cosmetic |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2661728T3 (en) | Compositions and methods for improved skin care | |
| TWI652066B (en) | Peptide for rejuvenating skin and method of use thereof | |
| JP4572003B2 (en) | Use of peptides for scarring, moisturizing and improving skin appearance as cosmetics or as dermatological agents during natural aging or hyperaging (sun dermatitis, contamination) | |
| US20100003340A1 (en) | Cosmetic compositions for the treatment of skin and methods thereof | |
| WO2014044808A2 (en) | Fast-penetration cosmetic dermal filler for topical application | |
| ES2617262T3 (en) | Cosmetic and pharmaceutical composition comprising N-acetylglucosamine 6-phosphate and a compound of the vitamin A family | |
| WO2008020954A2 (en) | Cosmetic composition to accelerate repair of functional wrinkles | |
| JP2017514825A (en) | Combination of hyaluronic acid and sulfated polysaccharide | |
| WO2009002982A2 (en) | Gastropod biological fluid, method of making and refining and use | |
| KR20190010795A (en) | Moisturizing, anti-wrinkling, and whitening cosmetic composition comprising novel Hyalpol Matrix Mixture and preparation method of the same | |
| KR20160131387A (en) | Composition for skin care | |
| CN104840385A (en) | A group of coenzyme Q10 skin protection creams with effects of skin moisturizing, wrinkle preventing and aging resistance | |
| Al-Halaseh et al. | A review of the cosmetic use and potentially therapeutic importance of hyaluronic acid | |
| IT202100028388A1 (en) | COSMETIC COMPOSITION | |
| ITRM20100540A1 (en) | "USE OF A PREPARATION BASED ON CAFFEINE MICRO-PATCH AND BETAGLUCAN POLYSACCHARIDES IN ANTI-WRINKLE TREATMENTS" | |
| CN107496194A (en) | A kind of surfactant and preparation method thereof | |
| RU2456977C1 (en) | Dry and very dry skin care preparation | |
| Weber et al. | Hand and foot moisturizers | |
| Schmidt et al. | Caring and Strengthening: the Global Skin Moisturization Strategy. | |
| Weber et al. | Hand and foot moisturizers | |
| ITRM20090079A1 (en) | NIFEDIPINE COMPOSITIONS FOR ANTI-WRINKLE TREATMENTS | |
| CN107496315A (en) | A kind of skin-care gel and preparation method thereof | |
| US20170196983A1 (en) | Topical composition replacing water with hyaluronic acid as the primary ingredient | |
| CA3227409A1 (en) | Composition of hyaluronic acid and use alone and in combination with retinoids to improve skin | |
| UA155585U (en) | Method of manufacturing facial toner |